NCT01883531View on ClinicalTrials.gov

Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years

PHASE2CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Cystic Fibrosis
Interventions
DRUG

Inhaled Mannitol

Active treatment is inhaled mannitol with a particle size of 3-4 microns

DRUG

Inhaled Placebo

The PLacebo is non respirable mannitol due to the big size particle

Trial Locations (1)

OX3 9DU

John Radcliffe Hospital, Oxford

Sponsors

Lead Sponsor

Syntara
All Listed Sponsors
lead

Syntara

INDUSTRY

NCT01883531 - Crossover Trial Determining the Efficacy of Dry Powder Mannitol to Improve Lung Function in Subjects Aged 6-17 Years | Biotech Hunter | Biotech Hunter